论文部分内容阅读
Ｓｕｌｐｅｒａｚｏｎｅ（青霉烷砜与头孢哌酮联合制剂缩写ＳＵＬ）是具有高效抗菌活性的抑酶增效联合制剂。本研究采用开放式随机对照方法评价ＳＵＬ治疗感染性疾患的安全有效性，选用头孢氨噻肟（ＣＴＸ）作为对照药。ＳＵＬ１．０－２．０ｇｉｖｑ１２ｈ；ＣＴＸ１．０－２．０ｇｉｖｑｉｄ。疗程均为７－１４ｄ。２７对呼吸系、泌尿系及皮肤软组织感染患者参加了试验。ＳＵＬ与ＣＴＸ的临床有效率分别为９６．３％和９２．６％；细菌清除率分别为７０．８％和６９．２％；不良反应分别为７．４％和１１．１％。两药间无统计学显著差异。细菌对药物敏感试验结果表明ＳＵＬ是所测药物（头孢氨噻肟、头孢哌酮、安灭菌、ｔｉｍｅｎｔｉｎ）中作用最强的一种，高度敏感菌达９５．９％，与其他所测药物相比有显著的统计学差异，Ｐ值＜０．００１。
Sulperazone (penicillin sulfone and cefoperazone combination preparation abbreviation SUL) is a synergistic inhibition synergistic combination of highly effective antibacterial activity. In this study, an open-label randomized controlled trial was conducted to evaluate the safety and efficacy of SUL in the treatment of infectious diseases. Cefotaxime (CTX) was selected as a reference drug. SUL 1.0-2.0 givq12h; CTX1.0-2.0 givqid. Treatment are 7-14d. 27 in respiratory, urinary tract and skin and soft tissue infections in patients participated in the trial. The clinical effective rates of SUL and CTX were 96.3% and 92.6% respectively; the bacterial clearance rates were 70.8% and 69.2% respectively; and the adverse reactions were 7.4% and 11.1% respectively. No significant difference between the two drugs. The results of bacterial susceptibility tests showed that SUL was the most potent one of the tested drugs (cefotaxime, cefoperazone, timentin) with a high sensitivity of 95.9%. Compared with other drugs tested There was a significant statistical difference compared to P <0.001.